Effect of genetic alterations of cytarabine-metabolizing enzymes in childhood acute lymphoblastic leukemia

Ravindranath, 2005, Pediatric Oncology Group. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000, Leukemia, 19, 2101, 10.1038/sj.leu.2403927 Momparler, 1972, Kinetic and template studies with 1 -b-D-Arabinofuranosylcytosine 5’-triphosphate and mammalian deoxyribonucleic acid polymerase, Mol Pharmacol, 8, 362 Kufe, 1980, Correlation of cytotoxicity with incorporation of ara-C into DNA, J Biol Chem, 255, 8997, 10.1016/S0021-9258(19)70512-2 Hamada, 2002, Clinical pharmacokinetics of cytarabine formulations, Clin Pharmacokinet, 41, 705, 10.2165/00003088-200241100-00002 Joerger, 2006, Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers, Eur J Clin Pharmacol, 62, 681, 10.1007/s00228-006-0162-7 Yue, 2003, A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity, Pharmacogenetics, 13, 29, 10.1097/00008571-200301000-00005 Shi, 2004, Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients, Pharmacogenetics, 14, 759, 10.1097/00008571-200411000-00007 Gilbert, 2006, Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics, Clin Cancer Res, 12, 1794, 10.1158/1078-0432.CCR-05-1969 Capizzi, 1984, Treatment of poor risk acute leukemia with sequential high-dose ARA-C and asparaginase, Blood, 63, 694 Silverman, 2007, Acute lymphoblastic leukemia in infancy, Pediatr Blood Cancer, 49, 1070, 10.1002/pbc.21352 Pui, 2004, Total Therapy Study XIIIB at St Jude Children’s Research Hospital. Improved outcome for children with acute lymphoblastic leukemia: results of total therapy study XIIIB at St Jude children's research hospital, Blood, 104, 2690, 10.1182/blood-2004-04-1616 Pui, 2004, Rational an design of total therapy study XV for newly diagnosed childhood acute lymphoblastic leukemia, Ann Hematol, 83, S124 Sugiyama, 2009, Ethnic differences of two non-synonymous single nucleotide polymorphisms in CDA gene, Drug Metab Pharmacokinet, 24, 553, 10.2133/dmpk.24.553 Bhatla, 2008, Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia, Br J Hematol, 144, 388, 10.1111/j.1365-2141.2008.07461.x Mahlknecht, 2009, SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival, Leukemia, 23, 1929, 10.1038/leu.2009.113 Campana, 2008, Status of minimal residual disease testing in childhood haematological malignancies, Br J Hematol, 143, 481 Motwani, 2008, Predictive value of flow cytometric minimal residual disease analysis in childhood acute lymphoblastic leukaemia at the end of remission induction therapy-results from a single UK centre, Br J Hematol, 144, 133, 10.1111/j.1365-2141.2008.07410.x Coustan-Smith, 2000, Clinical important of minimal residual disease in childhood acute lymphoblastic leukemia, Blood, 96, 2691, 10.1182/blood.V96.8.2691